SIC
DERM icon

SJS Investment Consulting’s Journey Medical DERM Stock Holding History

SJS Investment Consulting’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$116K – 2501
2025
Q4 		$116K Hold
15,000
– – 0.01% 188
2025
Q3 		$107K Buy
+15,000
New +$109K 0.01% 181

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SJS Investment Consulting's DERM Position: Q1 2026 in Review

SJS Investment Consulting sold out of Journey Medical (DERM) in Q1 2026, closing a stake of 15,000 shares — an estimated $116K sold.

SJS Investment Consulting first reported a position in DERM in Q3 2025 and held it in 2 quarters. The position peaked at $116K in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • SJS Investment Consulting reported no remaining Journey Medical position as of Q1 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 15,000 Journey Medical shares in Q1 2026, an estimated $116K.
  • SJS Investment Consulting first reported a position in Journey Medical in Q3 2025 and held it in 2 quarters.
  • SJS Investment Consulting's Journey Medical position peaked at $116K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.